


RealRate

## PHARMACEUTICAL 2018

## SPRING PHARMACEUTICAL GROUP INC. Rank 6 of 342







## PHARMACEUTICAL 2018



## SPRING PHARMACEUTICAL GROUP INC.

Rank 6 of 342

The relative strengths and weaknesses of SPRING PHARMACEUTICAL GROUP INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SPRING PHARMACEUTICAL GROUP INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 124% points. The greatest weakness of SPRING PHARMACEUTICAL GROUP INC. is the variable Other Expenses, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is 341%, being 296% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	12,043
Liabilities, Current	2,986
Liabilities, Non-Current	0
Other Assets	63,757
Other Compr. Net Income	-8,429
Other Expenses	43,263
Other Liabilities	0
Other Net Income	55
Other Revenues	56,463
Property and Equipment	14,487
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	90,287
Liabilities	2,986
Expenses	43,263
Revenues	56,463
Stockholders Equity	87,301
Net Income	13,255
Comprehensive Net Income	9,041
Economic Capital Ratio	341%

